ORPINGTON, England, July 2, 2024
/PRNewswire/ -- Specac, Ltd ("Specac"), a global leader in the
design and manufacture of spectroscopy accessories and sample prep
solutions and an Ampersand Capital Partners ("Ampersand") portfolio
company, is pleased to announce the appointment of Mark Dearden to its Board of Directors as
President and Chief Executive Officer (CEO), effective July 1, 2024.
Mr. Dearden is a seasoned international executive with over 30
years of experience in the life sciences industry dedicated to
scientific innovation and impactful outcomes. Upon joining the LGC
Group in 2011, Mr. Dearden served as Vice President of Strategy and
Marketing for the Genomics Division before being appointed its
Managing Director in July 2020. Prior
to LGC, Mr. Dearden held various international leadership positions
in general management, marketing, product management, and sales
with leading life sciences companies such as Amersham Biosciences,
GE Healthcare and Thermo Electron. Mr. Dearden holds a Bachelor of
Science with Honors from the University of
Sydney and an MBA from Warwick Business School.
Upon his appointment as CEO, Mr. Dearden commented, "I am
honored and thrilled to have the privilege of leading the teams at
Specac and its recently acquired Harrick division. I believe the
combined company has tremendous opportunities to build on its
strong product portfolio, global distribution reach and loyal
customer base. I look forward to leading the company through its
next phase of growth by leveraging these strengths and accelerating
product innovation."
Dave Patteson, an Ampersand
Partner, added, "Mark brings substantial, global experience from
the pharmaceutical, diagnostics and applied research market
sectors. As a seasoned executive, we are excited about the
contributions Mark will make as CEO to lead Specac's ambitious
growth strategy and drive value creation for all its
stakeholders."
About Specac, Ltd.
Specac and its Harrick division design and manufacture Fourier
Transform Infrared (FTIR) accessories, Sample Preparation/XRF,
Process Cells, and IR polarizer products for atomic and molecular
spectroscopy. These products include ATR accessories, specular
reflectance accessories, diffuse reflectance accessories, liquid
transmission and gas transmission cells, as well as infrared and
terahertz wire grid polarizers, bench-top hydraulic presses, KBr
pellet presses, XRF pellet presses, thin film-making kits and
evacuable pellet dies. For online optical spectroscopy or FTIR
analysis, Specac offers a comprehensive range of NIR Process Cells
suitable for liquid and gas/vapor analysis. Learn more
at specac.com.
About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market
private equity firm with $3 billion
of assets under management, dedicated to growth-oriented
investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information, visit
www.ampersandcapital.com or follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mark-dearden-named-chief-executive-officer-of-specac-ltd-302187557.html
SOURCE Specac, Ltd